BLAC SEC filings, in plain English
Everything Bellevue Life Sciences Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 12 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: OSR Health, Inc. filed an 8-K on August 28, 2026, reporting that the Nasdaq Hearings Panel scheduled a hearing for September 29, 2026, at 10:00 a.m. Eastern Time regarding the Company's appeal of a delisting determination. The filing states that trading in the Company’s securities was suspended effective August 26, 2026, but the timely hearing request stayed the filing of Form 25-NSE, preventing formal delisting pending the Panel's decision. The Company intends to present a plan to regain compliance with Nasdaq listing requirements and notes there is no assurance the Panel will grant continued listing. Why it matters: This filing confirms the procedural status of OSR Health's attempt to avoid delisting from Nasdaq; while trading remains suspended, the formal delisting process is paused until the September 29 hearing. For investors, this indicates the immediate risk of a completed delisting (Form 25-NSE) has been temporarily mitigated, but the underlying suspension of trading continues, creating liquidity constraints and uncertainty regarding the company's future listing status.
What changed: OSR Health, Inc. filed an 8-K on August 25, 2026, reporting that it submitted a request for a hearing before a Nasdaq Hearings Panel to appeal a Staff Determination Letter notifying the Company of Nasdaq’s determination to delist its common stock and warrants for non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The filing states that trading in the Company’s securities remains scheduled for suspension at the opening of business on August 26, 2026, because the timely hearing request does not stay this suspension. However, the request is expected to stay the filing of a Form 25-NSE, thereby delaying the formal delisting pending the Panel's decision. At the hearing, OSR Health intends to present a plan to evidence its ability to regain and sustain compliance with Nasdaq continued listing requirements. Why it matters: The document confirms that while the company has appealed the delisting determination, the immediate risk of trading suspension on August 26, 2026, remains unchanged. For investors tracking BLAC (Bellevue Life Sciences Acquisition Corp.), which is noted as CLOSED, this filing indicates that the merged entity (OSR Health) is facing significant regulatory hurdles regarding its market status, though no specific redemption deadlines or trust value changes are reported in this specific text.
What changed: OSR Health, Inc. received a Staff Determination Letter from Nasdaq on August 19, 2026 stating that Nasdaq has determined to delist its common stock and warrants from the Nasdaq Capital Market. The company was not in compliance with Listing Rule 5550(a)(2), the $1.00 minimum closing bid price, and Nasdaq concluded compliance could not be regained by the August 31, 2026 end of the compliance periods. Trading is to be suspended at the opening on August 26, 2026 and a Form 25-NSE filed. The company intends to request a Hearings Panel review by 4:00 p.m. ET on August 26, 2026. Why it matters: The filing states that because a second 180-day compliance period had already been granted, a timely hearing request will NOT stay the August 26 trading suspension; it is expected to stay only the Form 25-NSE and the final delisting pending the panel's decision. So the securities stop trading on Nasdaq regardless of the appeal, and the company itself says there is no assurance the request results in continued listing.
What changed: The 10-Q filed under Commission file number 001-41390 is that of OSR HEALTH, INC., formerly OSR HOLDINGS, INC. (Nasdaq: OSRH), for the quarter ended June 30, 2026, with 35,118,692 shares outstanding as of August 10, 2026 against 26,597,769 at December 31, 2025. Net sales fell to $315,669 for the quarter from $1,135,517 a year earlier and to $799,727 for the six months from $1,896,789, against selling, general and administrative expenses of $3,119,519 for the quarter, giving an operating loss of $3,032,915 and a net loss of $1,004,038 after $1,799,599 of other income. Why it matters: Roughly 98% of total assets are intangibles and goodwill against annualised sales of about $1.6 million, and the six-month comprehensive loss is nearly three times the net loss because of currency translation. The $28.8 million fall in non-controlling interests alongside a $36.3 million rise in paid-in capital indicates ownership moved from minority holders into the parent's equity during the period.
What changed: Item 5.07 8-K of OSR Health, Inc. (Nasdaq: OSRH) reporting its annual meeting held August 7, 2026. On the July 8, 2026 record date there were 35,118,692 shares outstanding, and 21,088,120 shares — approximately 60.05% — were represented, constituting a quorum. Seven directors were re-elected to serve until the 2027 annual meeting: Kuk Hyoun Hwang, Jun Chul Whang, Alcide Barberis, Seng Chin Mah, Hyuk Joo Jee, Joong Myung Cho and Reto Fierz, each with roughly 15.17 million votes for and 118,396 to 133,501 withheld. Why it matters: All proposals carried, including an increase in authorised shares — the filing states the vote but not the new authorised number, which is in the proxy statement filed July 16, 2026.
What changed: OSR Health, Inc. (Nasdaq: OSRH) reported under Item 7.01 that on August 7, 2026 it issued a press release clarifying its earlier press release of July 31, 2026 concerning communications with Nasdaq and its Shareholder Loyalty Contingent Value Rights program. Why it matters: The company is retracting an implication that the exchange had blessed the CVR programme — what Nasdaq actually said was a preliminary verbal answer to a mechanical price-adjustment question, not an approval. The August 14, 2026 record date stands, so holders' entitlement is unchanged even though the regulatory characterisation is.
What changed: 8-K of OSR Health, Inc. Item 7.01 (Regulation FD disclosure): on July 31, 2026 the Company issued a press release stating that Nasdaq, in a verbal communication with the Company, said its Shareholder Loyalty Contingent Value Rights program will not result in any mechanical adjustment to the price of the common stock, either on distribution of the CVRs or on delivery of additional shares to enrolled holders. The report states Nasdaq's position relates solely to price-adjustment treatment and is not an endorsement of the program or of an investment in the Company's securities. Why it matters: The disclosed fact is an oral statement by an exchange, furnished under Item 7.01 rather than filed, and the report itself says the separate securities-law requirements remain subject to the Company's ongoing regulatory process. Nothing here says the CVR program has been cleared to proceed.
What changed: OSR Health, Inc. (Nasdaq: OSRH), the successor to Bellevue Life Sciences Acquisition Corp, called its annual meeting for 7 August 2026 at 10:00 a.m. Eastern, virtual only. The proxy states plainly why the meeting is being held: to comply with Nasdaq Listing Rule 5620(a), which requires an annual meeting for the election of directors within 12 months of the fiscal year ended 31 December 2025. The company describes itself as a life sciences holding company, and the agenda includes an amendment proposal. Why it matters: The company says in its own words that the meeting exists to satisfy a listing rule rather than to put a decision to shareholders, which is what a compliance-driven calendar looks like rather than a business one. For Bellevue's sponsor track record the useful fact is simply that the successor is still listed and current with Nasdaq's governance requirements as of August 2026.
What changed: OSR Health, Inc. (Nasdaq: OSRH), the Bellevue Life Sciences Acquisition Corp. successor, filed the preliminary proxy for its annual meeting on August 7, 2026 at 10:00 a.m. ET, held entirely by webcast with a July 8, 2026 record date. The meeting satisfies Nasdaq Rule 5620(a), which requires a director election within twelve months of the December 31, 2025 year end. Stockholders are asked to raise authorised common stock from 100,000,000 to 250,000,000 shares. The outstanding share count is left blank in this preliminary version. Why it matters: This is the preliminary version of the proxy filed definitively on July 16, 2026, where the outstanding share count was completed at 35,118,692 — so the authorised share increase to 250,000,000 represents roughly seven times the shares in issue. For former BLAC holders that is the headroom management is asking for, and it is the single most consequential item on a ballot otherwise driven by a Nasdaq requirement to hold a meeting at all.
What changed: OSR Holdings, Inc. supplemented its May 26, 2026 definitive proxy statement to announce that on June 5, 2026 its board postponed the 2026 Annual Meeting of Stockholders, which had been set for June 18, 2026. The board determined that additional time was necessary to evaluate certain matters relating to the meeting and the business to be presented to stockholders. No new date has been established; the company says it will announce the rescheduled date, time and related information in a future filing with the SEC and through other appropriate communications. Why it matters: The scheduled meeting date on the public record is now void with no replacement, which is the state a calendar most easily gets wrong. The five proposals stand unchanged: electing seven directors; ratifying the auditor for the fiscal year ending December 31, 2026; an advisory say-on-pay vote; an amendment raising the 2025 Omnibus Incentive Plan reserve from 6,300,000 to 8,000,000 shares; and a charter amendment changing the legal name from OSR Holdings, Inc. to OSR Health, Inc. Holders who already submitted proxies are told to retain their materials pending further notice.
What changed: OSR Holdings, Inc. (Nasdaq: OSRH; successor to SPAC Bellevue Life Sciences Acquisition Corp) called an annual meeting for June 18, 2026 at 10:00 a.m., held in person at 10900 NE 4th Street, Suite 2300, Bellevue, Washington, record date May 6, 2026, when 35,104,695 shares of common stock were outstanding. Holders elect seven directors and vote on a charter amendment changing the legal name from OSR Holdings, Inc. to OSR Health, Inc. The meeting is held to satisfy Nasdaq Listing Rule 5620(a). Kuk Hyoun Hwang beneficially owns 13,069,106 shares, or 36.8%. Why it matters: Governance housekeeping rather than a capital event, but two facts matter to holders. Insider concentration is high: a single officer and director holds 36.8% of the 35.1 million shares outstanding, so board composition and any future issuance vote are effectively controlled from inside. The share count also traces sponsor-side conversions from the Bellevue SPAC, including 310,000 private placement rights converted into 31,000 shares and 60,000 private placement warrants exercised into 60,000 shares transferred to BCME under a promissory note.
- What changed vs 2025-04-22deadline 2025-09-30 → 2026-08-31
combination deadline, sponsor loans outstanding, trust account +11 moved · 3 with no prior record of ours
- Combination deadline
- 2025-09-302026-08-31
- Sponsor loans outstanding
- not previously extracted$2.9M
- Trust account
- $36.6Mnot matched in this filing
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as 335 days later than the previous record.
The clause …“Company an additional 180-day compliance period, extending the deadline to August 31, 2026, to regain compliance. If the Company does not regain compliance by that date, the Company’s securities may become subject to delisting from”…
The clause …“from April 11, 2026 to December 30, 2026. As of December 31, 2025, the total outstanding balance of loans receivable from OSR was $2,909,000, consisting of $175,000 outstanding under the Company Promissory Note described above and”…
The clause …“or even to offset the associated transaction and maintenance costs. There is substantial doubt about the Company’s ability to continue as a going concern, which could prevent the Company from executing its business plan and adversely”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: OSR Holdings, Inc., the successor to Bellevue Life Sciences Acquisition Corp., called its annual meeting for 9 a.m. Eastern time on September 17, 2025, with materials distributed on or about August 29, 2025, to elect seven directors. The business combination with Korea's OSR Holdings Co., Ltd. closed under an Amended and Restated Business Combination Agreement dated May 23, 2024 as amended December 20, 2024. Chief Executive Sang Hoon Kim received $84,020 and resigned as of August 26, 2025; Chairman Kuk Hyoun Hwang received nil. Why it matters: Tying RSU acceleration to business development agreements worth $300 million to $750 million in contracted value - rather than to revenue or earnings - rewards signing rather than performing, a structure that can produce large dilution from contracts that never generate cash. The chief executive resigning three weeks before the annual meeting compounds the uncertainty. The Bellevue trust was released at the de-SPAC and no floor remains.
trust account, combination deadlinenothing moved · 2 with no prior record of ours
- Trust account
- $2.0Mnot matched in this filing
- Combination deadline
- 2025-02-14not matched in this filing
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.